Cyclophilin B supports MYC and mutant p53-dependent survival of glioblastoma multiforme cells

Cancer Research

Volumn 74, Issue 2, 2014, Pages 484-496

  Choi, Jae Won ^a   Schroeder, Mark A ^a   Sarkaria, Jann N ^a   Bram, Richard J ^a  

^a MAYO CLINIC   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CHAPERONE; CHECKPOINT KINASE 1; CYCLOPHILIN B; CYCLOSPORIN A; JANUS KINASE; MYC PROTEIN; PROTEIN P53; REACTIVE OXYGEN METABOLITE; STAT3 PROTEIN;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CANCER SURVIVAL; CARCINOGENESIS; CELL PROLIFERATION; CELL SURVIVAL; CELL VIABILITY; CONTROLLED STUDY; ENDOPLASMIC RETICULUM STRESS; ENZYME INDUCTION; ENZYME INHIBITION; ENZYME REPRESSION; GENE EXPRESSION; GENE OVEREXPRESSION; GLIOBLASTOMA; HUMAN; HUMAN CELL; IN VITRO STUDY; IN VIVO STUDY; MOUSE; NONHUMAN; OXIDATIVE STRESS; PRIORITY JOURNAL; PROTEIN DEPLETION; PROTEIN FOLDING; SIGNAL TRANSDUCTION; UNFOLDED PROTEIN RESPONSE;

ANIMALS; ASTROCYTES; BETA-GALACTOSIDASE; BRAIN NEOPLASMS; CELL AGING; CELL PROLIFERATION; CELL SURVIVAL; CELL TRANSFORMATION, NEOPLASTIC; CYCLOPHILINS; GENE EXPRESSION REGULATION, ENZYMOLOGIC; GENE EXPRESSION REGULATION, NEOPLASTIC; GENES, P53; GLIOBLASTOMA; HUMANS; MICE; MICE, NUDE; MUTATION; NEOPLASM TRANSPLANTATION; NFATC TRANSCRIPTION FACTORS; PROTO-ONCOGENE PROTEINS C-MYC; REACTIVE OXYGEN SPECIES; TUMOR CELLS, CULTURED; TUMOR SUPPRESSOR PROTEIN P53;

EID: 84892918701     PISSN: 00085472     EISSN: 15387445     Source Type: Journal    
DOI: 10.1158/0008-5472.CAN-13-0771     Document Type: Article

References (43)

1. Chen J, McKay RM, Parada LF. Malignant glioma: lessons from genomics, mouse models, and stem cells. Cell 2012;149:36-47.
2. Louis DN, Ohgaki H, Wiestler OD, Cavenee WK, Burger PC, Jouvet A, et al. The 2007 WHO classification of tumours of the central nervous system. Acta Neuropathol 2007;114:97-109.
3. Handschumacher RE, Harding MW, Rice J, Drugge RJ, Speicher DW. Cyclophilin: a specific cytosolic binding protein for cyclosporin A. Science 1984;226:544-7.
4. Liu J, Albers MW, Chen CM, Schreiber SL, Walsh CT. Cloning, expression, and purification of human cyclophilin in Escherichia coli and assessment of the catalytic role of cysteines by site-directed mutagenesis. Proc Natl Acad Sci U S A 1990;87:2304-8.
5. Friedman J, Weissman I. Two cytoplasmic candidates for immunophilin action are revealed by affinity for a new cyclophilin: one in the presence and one in the absence of CsA. Cell 1991;66:799-806.
6. Liu J, Farmer JD Jr, Lane WS, Friedman J, Weissman I, Schreiber SL. Calcineurin is a common target of cyclophilin-cyclosporin A and FKBP-FK506 complexes. Cell 1991;66:807-15.
7. Price ER, Zydowsky LD, Jin MJ, Baker CH, McKeon FD, Walsh CT. Human cyclophilin B: a second cyclophilin gene encodes a peptidylprolyl isomerase with a signal sequence. Proc Natl Acad Sci U S A 1991;88:1903-7.
8. Kim Y, Jang M, Lim S, Won H, Yoon KS, Park JH. Role of cyclophilin B in tumorigenesis and cisplatin resistance in hepatocellular carcinoma in humans. Hepatology 2011;54:1661-78.
9. Watashi K, Ishii N, Hijikata M, Inoue D, Murata T, Miyanari Y. Cyclophilin B is a functional regulator of hepatitis C virus RNA polymerase. Mol Cell 2005;19:111-22.
10. Swanson SK, Born T, Zydowsky LD, Cho H, Chang HY, Walsh CT, et al. Cyclosporin-mediated inhibition of bovine calcineurin by cyclophilins A and B. Proc Natl Acad Sci U S A 1992;89:3741-5.
11. Bukrinsky MI. Cyclophilins: unexpected messengers in intercellular communications. Trends Immunol 2002;23:323-5.
12. Rycyzyn MA, Reilly SC, O'Malley K, Clevenger CV. Role of cyclophilin B in prolactin signal transduction and nuclear retrotranslocation. Mol Endocrinol 2000;14:1175-86.
13. Choi JW, Sutor SL, Lindquist L, Evans GL, Madden BJ, Bergen HR III, et al. Severe osteogenesis imperfecta in cyclophilin B-deficient mice. PLoS Genet 2009;5:e1000750.
14. Kim J, Choi TG, Ding Y, Kim Y, Ha KS, Lee KH, et al. Overexpressed cyclophilin B suppresses apoptosis associated with ROS and Ca2+ homeostasis after ER stress. J Cell Sci 2008;121:3636-48.
15. Bauer K, Kretzschmar AK, Cvijic H, Blumert C, Loffler D, Brocke-Heidrich K, et al. Cyclophilins contribute to Stat3 signaling and survival of multiple myeloma cells. Oncogene 2009;28:2784-95.
16. Carlson BL, Pokorny JL, Schroeder MA, Sarkaria JN. Establishment, maintenance and in vitro and in vivo applications of primary human glioblastoma multiforme (GBM) xenograft models for translational biology studies and drug discovery. Curr Protoc Pharmacol 2011; Chapter 14:Unit 14.16.
17. Belshaw PJ, Ho SN, Crabtree GR, Schreiber SL. Controlling protein association and subcellular localization with a synthetic ligand that induces heterodimerization of proteins. Proc Natl Acad Sci U S A 1996;93:4604-7.
18. Wu YQ, Belyakov S, Choi C, Limburg D, Thomas IB, Vaal M, et al. Synthesis and biological evaluation of non-peptidic cyclophilin ligands. J Med Chem 2003;46:1112-5.
19. Iwamaru A, Szymanski S, Iwado E, Aoki H, Yokoyama T, Fokt I, et al. A novel inhibitor of the STAT3 pathway induces apoptosis in malignant glioma cells both in vitro and in vivo. Oncogene 2007;26:2435-44.
20. Baffy G, Derdak Z, Robson SC. Mitochondrial recoupling: a novel therapeutic strategy for cancer? Br J Cancer 2011;105:469-74.
21. Mason DX, Jackson TJ, Lin AW. Molecular signature of oncogenic rasinduced senescence. Oncogene 2004;23:9238-46.
22. Hanafusa H, Torii S, Yasunaga T, Nishida E. Sprouty1 and Sprouty2 provide a control mechanism for the Ras/MAPK signalling pathway. Nat Cell Biol 2002;4:850-8.
23. Britson JS, Barton F, Balko JM, Black EP. Deregulation of DUSP activity in EGFR-mutant lung cancer cell lines contributes to sustained ERK1/2 signaling. Biochem Biophys Res Commun 2009;390:849-54.
24. Sa G, Stacey DW. P27 expression is regulated by separate signaling pathways, downstream of Ras, in each cell cycle phase. Exp Cell Res 2004;300:427-39.
25. Bachireddy P, Bendapudi PK, Felsher DW. Getting at MYC through RAS. Clin Cancer Res 2005;11:4278-81.
26. Dang CV. MYC on the path to cancer. Cell 2012;149:22-35.
27. Adamo L, Zhang Y, Garcia-Cardena G. AICAR activates the pluripotency transcriptional network in embryonic stem cells and induces KLF4 and KLF2 expression in fibroblasts. BMC Pharmacol 2009;9:2.
28. Huang MJ, Cheng YC, Liu CR, Lin S, Liu HE. A small-molecule c-Myc inhibitor, 10058-F4, induces cell-cycle arrest, apoptosis, and myeloid differentiation of human acute myeloid leukemia. Exp Hematol 2006;34:1480-9.
29. Cairns RA, Harris IS, Mak TW. Regulation of cancer cell metabolism. Nat Rev Cancer 2011;11:85-95.
30. Bartek J, Bartkova J, Lukas J. DNA damage signalling guards against activated oncogenes and tumour progression. Oncogene 2007;26:7773-9.
31. Dai Y, Grant S. New insights into checkpoint kinase 1 in the DNA damage response signaling network. Clin Cancer Res 2010;16:376-83.
32. Walter P, Ron D. The unfolded protein response: from stress pathway to homeostatic regulation. Science 2011;334:1081-6.
33. Salazar M, Carracedo A, Salanueva IJ, Hernandez-Tiedra S, Lorente M, Egia A, et al. Cannabinoid action induces autophagy-mediated cell death through stimulation of ER stress in human glioma cells. J Clin Invest 2009;119:1359-72.
34. Fang F, Zheng J, Galbaugh TL, Fiorillo AA, Hjort EE, Zeng X, et al. Cyclophilin B as a co-regulator of prolactin-induced gene expression and function in breast cancer cells. J Mol Endocrinol 2010;44:319-29.
35. Williams PD, Owens CR, Dziegielewski J, Moskaluk CA, Read PW, Larner JM, et al. Cyclophilin B expression is associated with in vitro radioresistance and clinical outcome after radiotherapy. Neoplasia 2011;13:1122-31.
36. Ferrao PT, Bukczynska EP, Johnstone RW, McArthur GA. Efficacy of CHK inhibitors as single agents in MYC-driven lymphoma cells. Oncogene 2012;31:1661-72.
37. Freed-Pastor WA, Prives C. Mutant p53: one name, many proteins. Genes Dev 2012;26:1268-86.
38. Merksamer PI, Trusina A, Papa FR. Real-time redox measurements during endoplasmic reticulum stress reveal interlinked protein folding functions. Cell 2008;135:933-47.
39. Bernasconi R, Solda T, Galli C, Pertel T, Luban J, Molinari M. Cyclosporine A-sensitive, cyclophilin B-dependent endoplasmic reticulum-associated degradation. PLoS ONE 2010;5:e13008.
40. Nardella C, Clohessy JG, Alimonti A, Pandolfi PP. Pro-senescence therapy for cancer treatment. Nat Rev Cancer 2011;11:503-11.
41. Kuilman T, Peeper DS. Senescence-messaging secretome: SMS-ing cellular stress. Nat Rev Cancer 2009;9:81-94.
42. Xu W, Trepel J, Neckers L. Ras, ROS and proteotoxic stress: a delicate balance. Cancer Cell 2011;20:281-2.
43. Schubert A, Grimm S. Cyclophilin D, a component of the permeability transition-pore, isan apoptosis repressor. Cancer Res 2004;64:85-93.